Lilly’s Q1 2025 revenue jumps 45%, but CVS shift boosts Novo’s Wegovy
Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.
Therapy Area
New £1bn cancer research hub planned for South London
GSK’s Zejula reduces risk of progression and death in mesothelioma study
Boehringer, Oxford University and Cumulus to explore brain activity in BPD
AstraZeneca’s Truqap fails in another Phase III trial
Myostatin inhibitors target muscle loss prevention to fill gap in GLP-1RA market
UK MHRA authorises BridgeBio’s acoramidis for ATTR-CM
Biohaven secures $600m financing as it awaits FDA prodrug decision
